Corbus Pharmaceuticals
Develops CRB-701 for oncology and CRB-913 for obesity.
$11.10
After-hours close+0.19 (+1.79%)
At close$10.91(−2.02%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 3.15%
Shares outstanding 18.53M · Float 14.32M · 77.3% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 13.36% | 2.34M | 13G | Dec 15, 2025 ↗ |
| Octagon Investments Master Fund LPincl. Octagon Capital Advisors LP, Ting Jia | 9.30% | 1.12M | 13G | Oct 11, 2024 ↗ |
| Aberdeen Group plc | 7.53% | 1.32M | 13G | Jan 16, 2026 ↗ |
| BlackRock, Inc. | 5.90% | 1.09M | 13G | Jul 27, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 10 percent owner | 2.34M | 12.66% | Dec 15, 2025 |
| Yuval Cohen | director, officer: Chief Executive Officer | 157.3K | 0.85% | Aug 10, 2026 |
| Dominic Smethurst | officer: Chief Medical Officer | 89.8K | 0.48% | Mar 4, 2026 |
| Sean F. Moran | officer: Chief Financial Officer | 84.7K | 0.46% | Aug 10, 2026 |
| Nishant C. Saxena | officer: Chief Business Officer | 77.9K | 0.42% | Aug 12, 2026 |
| Leonardo Viana Nicacio | officer: Chief Medical Officer | 58.3K | 0.31% | Aug 17, 2026 |
| Ian Hodgson | officer: Chief Operating Officer | 51.1K | 0.28% | Feb 18, 2026 |
| Winston Kung | director | 12.1K | 0.07% | Jun 11, 2026 |
| Yong Ben | director | 11.4K | 0.06% | May 21, 2026 |
| Rachelle Suzanne Jacques | director | 11.4K | 0.06% | May 21, 2026 |
3 ten-percent owners hold 2.56M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 9 people have not refiled in the last 18 months (87.5K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 11, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 2,600 | $9.63 | 77,900 |
| Aug 7, 2026 | Sean F. Moranofficer: Chief Financial Officer | Sale | 12,000 | $10.08 | 84,694 |
| Aug 7, 2026 | Yuval Cohendirector, officer: Chief Executive Officer | Sale | 17,000 | $10.08 | 157,316 |
| Jun 10, 2026 | John Kenneth Jenkinsdirector | Sale | 4,800 | $7.91 | 3,833 |
| Jun 10, 2026 | Anne Altmeyerdirector | Sale | 2,412 | $7.91 | 7,579 |
| Jun 10, 2026 | Winston Kungdirector | Sale | 2,026 | $7.91 | 12,140 |
| Jun 2, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 4,500 | $7.33 | 66,300 |
| Jun 3, 2026 | Nishant C. Saxenaofficer: Chief Business Officer | Purchase | 9,000 | $7.58 | 75,300 |
| Mar 2, 2026 | Dominic Smethurstofficer: Chief Medical Officer | Sale | 6,097 | $8.30 | 89,790 |
| Feb 13, 2026 | Yuval Cohendirector, officer: Chief Executive Officer | Sale | 13,871 | $7.78 | 174,316 |
CongressHouse and Senate disclosures
Not reported.